Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-Life Cefiderocol Use in Bone and Joint Infection: A French National Cohort.
Diarra A, Degrendel M, Eberl I, Ferry T, Jaffal K, Escaut L, Khati AA, Taar N, Courjon J, Deconinck L, Lefevre B, Baldolli A, Bermejo M, Bleibtreu A, Dacquet V, de Lastours V, Gazeau P, Larcher R, Patoz P, Robineau O, Rouzic N, Sayre N, Costescu Strachinaru DI, Valentin B, Wille H, Senneville E. Diarra A, et al. Among authors: courjon j. Antibiotics (Basel). 2025 Apr 8;14(4):388. doi: 10.3390/antibiotics14040388. Antibiotics (Basel). 2025. PMID: 40298564 Free PMC article.
French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A, Duran C, Pavese P, Khatchatourian L, Monnin B, Bleibtreu A, Denis E, Etienne C, Rouanes N, Mahieu R, Bouchand F, Davido B, Lotte R, Cabaret P, Camou F, Chavanet P, Assi A, Limonta S, Lechiche C, Riou R, Courjon J, Illes G, Lacassin-Beller F, Senneville E; Dalbavancin French Study Group. Dinh A, et al. Among authors: courjon j. Int J Antimicrob Agents. 2019 Nov;54(5):668-672. doi: 10.1016/j.ijantimicag.2019.08.006. Epub 2019 Aug 7. Int J Antimicrob Agents. 2019. PMID: 31400471
Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
Matt M, Duran C, Courjon J, Lotte R, Moing VL, Monnin B, Pavese P, Chavanet P, Khatchatourian L, Tattevin P, Cattoir V, Lechiche C, Illes G, Lacassin-Beller F, Senneville E, Dinh A; Dalbavancin French Study Group. Matt M, et al. Among authors: courjon j. J Glob Antimicrob Resist. 2021 Jun;25:341-345. doi: 10.1016/j.jgar.2021.03.026. Epub 2021 May 4. J Glob Antimicrob Resist. 2021. PMID: 33962065 Free article. Review.
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group. Ader F, et al. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14. Lancet Infect Dis. 2022. PMID: 34534511 Free PMC article. Clinical Trial.
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.
Terzić V, Miantezila Basilua J, Billard N, de Gastines L, Belhadi D, Fougerou-Leurent C, Peiffer-Smadja N, Mercier N, Delmas C, Ferrane A, Dechanet A, Poissy J, Espérou H, Ader F, Hites M, Andrejak C, Greil R, Paiva JA, Staub T, Tacconelli E, Burdet C, Costagliola D, Mentré F, Yazdanpanah Y, Diallo A; DisCoVeRy Study Group. Terzić V, et al. Clin Infect Dis. 2024 Aug 16;79(2):382-391. doi: 10.1093/cid/ciae170. Clin Infect Dis. 2024. PMID: 38552208 Free PMC article. Clinical Trial.
287 results